For research and educational purposes only. Not intended for human consumption.
Dihexa
Limited Research- •⚠️ LIFT-AD trial FAILED (Sept 2024)
- •Key studies RETRACTED for data issues
- •c-Met cancer risk warning added
- •No active clinical development
Synaptogenic Peptide | Cognitive Enhancement & Neuroprotection
Overview
What is Dihexa?
Dihexa is a synthetic hexapeptide originally developed at Washington State University as a cognitive enhancer. CRITICAL UPDATE (September 2024): Athira Pharma's LIFT-AD trial of fosgonimeton (a clinical Dihexa derivative) FAILED to meet primary and secondary endpoints in 312 mild-to-moderate Alzheimer's patients, representing a significant gap between animal data and clinical reality. Additionally, key foundational studies were retracted due to data integrity issues.
Key Benefits
Animal models showed remarkable synaptogenesis (10 million times more potent than BDNF) and cognitive improvements. However, clinical trials of derivative compound failed in humans. Mechanism (HGF/c-Met activation) remains scientifically sound but clinical translation unsuccessful.
Mechanism of Action
Dihexa potentiates hepatocyte growth factor (HGF) activity and stimulates c-Met receptor pathway for synaptogenesis. CRITICAL SAFETY CONCERN: c-Met pathway is a known proto-oncogene, raising serious theoretical risks of tumor growth or cancer progression with chronic use. No long-term human toxicology studies exist.
Molecular Information
Pharmacokinetics
Research Indications
Memory Enhancement
Significant improvements in spatial memory, working memory, and memory consolidation in animal models.
Learning Acceleration
Enhanced acquisition of new information and skills through increased synaptic plasticity.
Cognitive Recovery
Restoration of cognitive function in models of impairment, including scopolamine-induced amnesia.
Research Protocols
Disclaimer: Dihexa is not FDA approved and has limited human data. These protocols are based on animal research and anecdotal reports. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Research-Based Injectable | 0.5mg/kg | 1x daily | IP/SubQ |
| Cognitive Enhancement | 8-10mg | 1x daily (morning) | Oral |
| Intensive Learning | 10-15mg | 1x daily | Oral |
| Neuroprotection | 5-8mg | Daily or 3x weekly | Oral or SubQ |
| Maintenance | 5mg | Every other day | Oral |
Timing: Morning dosing recommended for cognitive enhancement. Oral capsules can be taken with or without food. Injectable requires DMSO solvent.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Dihexa does NOT dissolve in water - must use DMSO as solvent
For a 10mg vial: add 100 µL (0.1 mL) of pharmaceutical-grade DMSO
Add 400 µL (0.4 mL) PEG300 and gently swirl until clear
Add 50 µL (0.05 mL) Tween 80 and gently swirl until clear
Add 450 µL (0.45 mL) sterile saline and gently swirl
Final ratio: 10% DMSO / 40% PEG300 / 5% Tween 80 / 45% saline
Store at 2-8°C, use within 30 days
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Pharmaceutical Grade
Product from licensed source with certificate of analysis showing >98% purity.
Proper Storage Conditions
Room temperature for oral, 2-8°C for DMSO stock solutions.
Research Chemical Source
If sourced as research chemical, ensure third-party testing.
No Testing Documentation
Avoid products without analytical testing or purity reports.
Suspicious Pricing
Extremely cheap Dihexa likely indicates poor quality.
What to Expect
- •Week 1-2: Subtle cognitive changes, possible headaches
- •Week 2-4: Improved focus and memory formation
- •Week 4-8: Peak cognitive benefits, enhanced learning
- •Post-cycle: Effects may persist for days to weeks
- •Side effects: Headaches (most common), anxiety, sleep disruption if taken late
Side Effects & Safety
Side Effects
- •Not FDA approved - research compound only
- •Theoretical cancer risk via c-Met activation
- •No long-term human safety data available
- •Avoid if history of cancer
- •Not for pregnant/nursing women
- •May cause overstimulation or anxiety
- •Requires cycling to prevent tolerance
When to Stop
- •Severe headaches
- •Persistent anxiety
- •Sleep disruption
- •Signs of overstimulation
- •Consult healthcare provider
References
4 StudiesLIFT-AD Clinical Trial FAILURE (September 2024)
Human | 312 patients | Mild-moderate AD | Fosgonimeton | FAILED primary and secondary endpoints
CRITICAL: Athira Pharma's fosgonimeton (clinical Dihexa derivative) failed to meet any primary or secondary endpoints in humans with Alzheimer's disease. Represents significant gap between animal data and clinical reality.
Study Retractions - Data Integrity Issues
Multiple foundational studies | Key papers retracted
Multiple foundational studies supporting Dihexa's mechanism have been retracted due to data integrity issues, undermining the scientific foundation.
APP/PS1 Alzheimer's Mouse Model (2021)
Mice | 1.44-2.88 mg/kg oral | 3 months | Cognitive rescue via PI3K/AKT
In animal models (not humans), Dihexa restored spatial learning and memory, increased neuronal cells and synaptophysin expression, reduced neuroinflammation in AD model mice.
View StudyQuick Start Guide
Research Disclaimer
Dihexa is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Dihexa must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Dihexa for any purpose. Consult qualified professionals for any research applications.